aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel functions of tRNA synthetases in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase 3 clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of SSc-ILD and other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. The company is developing ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase that is in preclinical development for the treatment of fibrosis; and ATYR0750, a domain of alanyl-tRNA synthetase for the treatment of liver disorders. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. aTyr Pharma, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

aTyr Pharma, Inc.

Wells Fargo analyst Derek Archila maintained a Hold rating on aTyr Pharma today and set a price target of $1.00. According to TipRanks, Archila is ...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ATYR	$0.49	-2.03%	115.78K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ATYR	$0.49	-2.0%	115.78K
3
4
5
6

ATYR

Get aTyr Pharma, Inc. Data in Excel

Get aTyr Pharma, Inc. Data in Excel